» Authors » Consuelo Soldevila-Pico

Consuelo Soldevila-Pico

Explore the profile of Consuelo Soldevila-Pico including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 812
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang D, Hart J, Ding X, Zhang X, Feely M, Yassan L, et al.
Gastroenterol Rep (Oxf) . 2020 May; 8(1):50-55. PMID: 32467761
Background: Nivolumab and pembrolizumab-two monoclonal antibodies that block human programmed cell death-1 (PD-1)-have been successfully used to treat patients with multiple advanced malignancies. The histologic patterns of hepatic toxicity induced...
2.
Zori A, Ismael M, Limaye A, Firpi R, Morelli G, Soldevila-Pico C, et al.
Am J Clin Oncol . 2020 Feb; 43(5):325-333. PMID: 32079854
Objective: The objective of this study was to compare posttransplant outcomes in patients undergoing bridging locoregional therapy (LRT) with Y-90 transarterial radioembolization (TARE) based protocol compared with transarterial chemoembolization based...
3.
Bril F, McPhaul M, Caulfield M, Castille J, Poynard T, Soldevila-Pico C, et al.
J Investig Med . 2018 Oct; 67(2):303-311. PMID: 30309884
Fibromax is a diagnostic tool composed of the combination of 4 non-invasive biomarker panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and NashTest-2) and fibrosis (FibroTest). The...
4.
Kwo P, Fried M, Reddy K, Soldevila-Pico C, Khemichian S, Darling J, et al.
Hepatol Commun . 2018 Apr; 2(4):354-363. PMID: 29619415
We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child-Pugh class...
5.
Riverso M, Chang M, Soldevila-Pico C, Lai J, Liu X
Gastroenterology Res . 2018 Mar; 11(1):79-82. PMID: 29511414
Kratom is an herbal product derived from the leaves of Southeast Asian trees. It has traditionally been used by indigenous people to relieve fatigue and manage pain, diarrhea, or opioid...
6.
Bril F, Kalavalapalli S, Clark V, Lomonaco R, Soldevila-Pico C, Liu I, et al.
Clin Gastroenterol Hepatol . 2017 Dec; 16(4):558-566.e2. PMID: 29223443
Background & Aims: Pioglitazone is effective for long-term treatment of patients with nonalcoholic steatohepatitis (NASH) with prediabetes or type 2 diabetes. However, it is not clear how the presence of...
7.
Dhanasekaran R, Hemming A, Zendejas I, George T, Nelson D, Soldevila-Pico C, et al.
Oncol Rep . 2013 Feb; 29(4):1259-67. PMID: 23426976
The aim of the present study was to determine the treatment outcome and prognostic factors for survival in patients with peripheral intrahepatic cholangiocarcinoma (ICC). A retrospective chart review was performed...
8.
Michaels A, Dhanasekaran R, Foley D, Alkhasawneh A, Dixon L, Soldevila-Pico C, et al.
Dig Dis Sci . 2013 Jan; 58(5):1403-9. PMID: 23306846
Background: Preservation injury in the HCV liver transplant population has been reported to correlate with poorer survival outcomes compared to preservation injury in the non-HCV liver transplant population. However, determinants...
9.
Limaye A, Clark V, Soldevila-Pico C, Morelli G, Suman A, Firpi R, et al.
Hepatol Res . 2012 Dec; 43(7):757-64. PMID: 23193965
Aim: The goal of this study is to evaluate whether an elevated neutrophil-lymphocyte ratio (NLR) at the time of diagnosis predicts survival of patients with hepatocellular carcinoma (HCC) after liver...
10.
Firpi R, Dong H, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, et al.
Liver Int . 2012 Oct; 33(1):72-8. PMID: 23107586
Background/aims: Interleukin-28B (IL-28B) polymorphism is the strongest pretreatment predictor of viral clearance in the hepatitis C (HCV) population. Donor and recipient IL-28B genomic background may play an important role in...